CN108778317A - 用于心血管病况的利拉鲁肽 - Google Patents

用于心血管病况的利拉鲁肽 Download PDF

Info

Publication number
CN108778317A
CN108778317A CN201780015266.5A CN201780015266A CN108778317A CN 108778317 A CN108778317 A CN 108778317A CN 201780015266 A CN201780015266 A CN 201780015266A CN 108778317 A CN108778317 A CN 108778317A
Authority
CN
China
Prior art keywords
subject
placebo
liraglutide
mace
compared
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780015266.5A
Other languages
English (en)
Chinese (zh)
Inventor
S.拉斯姆森
K.卡维斯特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59723004&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN108778317(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Priority to CN202310320736.6A priority Critical patent/CN116327897A/zh
Publication of CN108778317A publication Critical patent/CN108778317A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
CN201780015266.5A 2016-03-04 2017-03-03 用于心血管病况的利拉鲁肽 Pending CN108778317A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202310320736.6A CN116327897A (zh) 2016-03-04 2017-03-03 用于心血管病况的利拉鲁肽

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
EP16158739 2016-03-04
EP16158739.9 2016-03-04
EP16173917.2 2016-06-10
EP16173917 2016-06-10
EP16001329.8 2016-06-13
EP16001329 2016-06-13
US15/401,651 US9968659B2 (en) 2016-03-04 2017-01-09 Liraglutide in cardiovascular conditions
US15/401651 2017-01-09
PCT/EP2017/054990 WO2017149112A1 (en) 2016-03-04 2017-03-03 Liraglutide in cardiovascular conditions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202310320736.6A Division CN116327897A (zh) 2016-03-04 2017-03-03 用于心血管病况的利拉鲁肽

Publications (1)

Publication Number Publication Date
CN108778317A true CN108778317A (zh) 2018-11-09

Family

ID=59723004

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201780015266.5A Pending CN108778317A (zh) 2016-03-04 2017-03-03 用于心血管病况的利拉鲁肽
CN202310320736.6A Pending CN116327897A (zh) 2016-03-04 2017-03-03 用于心血管病况的利拉鲁肽

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202310320736.6A Pending CN116327897A (zh) 2016-03-04 2017-03-03 用于心血管病况的利拉鲁肽

Country Status (24)

Country Link
US (2) US9968659B2 (enExample)
EP (1) EP3423082B1 (enExample)
JP (1) JP6940512B2 (enExample)
KR (1) KR102417455B1 (enExample)
CN (2) CN108778317A (enExample)
AU (2) AU2017225841A1 (enExample)
BR (1) BR112018067344A2 (enExample)
CA (1) CA3013532C (enExample)
CL (1) CL2018002515A1 (enExample)
DK (1) DK3423082T5 (enExample)
ES (1) ES2893755T3 (enExample)
HR (1) HRP20211492T1 (enExample)
HU (1) HUE055844T2 (enExample)
IL (1) IL261169B (enExample)
MA (1) MA43704A (enExample)
MX (1) MX394179B (enExample)
MY (1) MY195657A (enExample)
PH (1) PH12018501844B1 (enExample)
PL (1) PL3423082T3 (enExample)
RS (1) RS62501B1 (enExample)
RU (1) RU2745604C2 (enExample)
SI (1) SI3423082T1 (enExample)
WO (1) WO2017149112A1 (enExample)
ZA (1) ZA201805538B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9968659B2 (en) 2016-03-04 2018-05-15 Novo Nordisk A/S Liraglutide in cardiovascular conditions
CA3177693A1 (en) 2019-04-05 2020-10-05 Eli Lilly And Company Therapeutic uses of dulaglutide
CN118987224A (zh) * 2020-12-16 2024-11-22 香港中文大学 一种治疗受试者的衰老相关脑功能障碍的组合物及其应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030220255A1 (en) * 2002-04-04 2003-11-27 Knudsen Liselotte Bjerre GLP-1 agonist and cardiovascular complications
CN1882356A (zh) * 2003-11-20 2006-12-20 诺沃挪第克公司 对于生产和用于注射装置中是最佳的含有丙二醇的肽制剂
CN101056650A (zh) * 2004-11-12 2007-10-17 诺和诺德公司 促胰岛素肽的稳定制剂
CN101868476A (zh) * 2007-09-05 2010-10-20 诺沃-诺迪斯克有限公司 胰高血糖素样肽-1衍生物及其制药用途
CN103893744A (zh) * 2012-12-24 2014-07-02 杭州九源基因工程有限公司 一种治疗糖尿病的药物制剂及其制备方法
CN104136014A (zh) * 2011-12-29 2014-11-05 勃林格殷格翰国际有限公司 Dpp-4抑制剂的皮下治疗用途

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5808203A (en) 1997-05-12 1998-09-15 Medrad, Inc. Fluid pressure measurement devices
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
AR075204A1 (es) 2009-01-29 2011-03-16 Boehringer Ingelheim Int Inhibidores de dpp-4 y composiciones farmaceuticas que los comprenden, utiles para tratar enfermedades metabolicas en pacientes pediatricos, particularmente diabetes mellitus tipo 2
KR20110135411A (ko) 2009-03-27 2011-12-16 브리스톨-마이어스 스큅 컴퍼니 Ｄｐｐ-ｉｖ 억제제로 주요 유해 심장혈관 이벤트를 예방하는 방법
WO2011140176A1 (en) 2010-05-04 2011-11-10 Glaxosmithkline Llc Methods for treating or preventing cardiovascular disorders and providing cardiovascular protection
KR20230051307A (ko) 2010-06-24 2023-04-17 베링거 인겔하임 인터내셔날 게엠베하 당뇨병 요법
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
US20130303462A1 (en) 2012-05-14 2013-11-14 Boehringer Ingelheim International Gmbh Use of a dpp-4 inhibitor in podocytes related disorders and/or nephrotic syndrome
EP4151218A1 (en) 2012-05-14 2023-03-22 Boehringer Ingelheim International GmbH Linagliptin, a xanthine derivative as dpp-4 inhibitor, for use in the treatment of sirs and/or sepsis
JP6374862B2 (ja) 2012-05-24 2018-08-15 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 自己免疫性糖尿病、特に、ｌａｄａの治療に使用するためのｄｐｐ−４阻害剤としてのキサンチン誘導体
JP2016510795A (ja) 2013-03-15 2016-04-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 心臓保護及び腎臓保護の抗糖尿病治療におけるリナグリプチンの使用
JP6507154B2 (ja) 2013-06-14 2019-04-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 糖尿病及びその合併症を治療するためのｄｄｐ−４阻害薬
US8969371B1 (en) 2013-12-06 2015-03-03 Orexigen Therapeutics, Inc. Compositions and methods for weight loss in at risk patient populations
EP3110449B1 (en) 2014-02-28 2023-06-28 Boehringer Ingelheim International GmbH Medical use of a dpp-4 inhibitor
WO2016019587A1 (en) 2014-08-08 2016-02-11 Merck Sharp & Dohme Corp. [7, 6]-fused bicyclic antidiabetic compounds
US9968659B2 (en) 2016-03-04 2018-05-15 Novo Nordisk A/S Liraglutide in cardiovascular conditions

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030220255A1 (en) * 2002-04-04 2003-11-27 Knudsen Liselotte Bjerre GLP-1 agonist and cardiovascular complications
CN1882356A (zh) * 2003-11-20 2006-12-20 诺沃挪第克公司 对于生产和用于注射装置中是最佳的含有丙二醇的肽制剂
CN101056650A (zh) * 2004-11-12 2007-10-17 诺和诺德公司 促胰岛素肽的稳定制剂
CN101868476A (zh) * 2007-09-05 2010-10-20 诺沃-诺迪斯克有限公司 胰高血糖素样肽-1衍生物及其制药用途
CN104136014A (zh) * 2011-12-29 2014-11-05 勃林格殷格翰国际有限公司 Dpp-4抑制剂的皮下治疗用途
CN103893744A (zh) * 2012-12-24 2014-07-02 杭州九源基因工程有限公司 一种治疗糖尿病的药物制剂及其制备方法

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
G. H. DANIELS ET AL.: "LEADER 2: baseline calcitonin in 9340 people with type 2 diabetes enrolled in the Liraglutide Effect and Action in Diabetes: Evaluation of cardiovascular outcome Results (LEADER) trial: preliminary observations", 《DIABETES, OBESITY AND METABOLISM》 *
IAN D CATERSON ET AL.: "Cardiovascular Safety of Liraglutide: Pooled Analysis of Major Adverse Cardiovascular Events across Weight Management and Type 2 Diabetes Development Programs", 《CIRCULATION》 *
L. MASMIQUEL ET AL.: "LEADER 5: prevalence and cardiometabolic impact of obesity in cardiovascular high‑risk patients with type 2 diabetes mellitus: baseline global data from the LEADER trial", 《CARDIOVASC DIABETOL》 *
MANFREDI RIZZO ET AL.: "Liraglutide Reduces Oxidative Stress And Restores Heme Oxygenase-1 and Ghrelin Levels in Patients with Type 2 Diabetes: A Prospective Pilot Study", 《J CLIN ENDOCRINOL METAB》 *
STEVEN P. MARSO ET AL.: "Design of the liraglutide effect and action in diabetes: Evaluation of cardiovascular outcome results (LEADER) trial", 《AMERICAN HEART JOURNAL》 *
V.FONSECA ET AL.: "a meta-analysis of six clinical trials demonstrates that the once-daily human glp-1 analogue liraglutide reduces systolic blood pressure", 《DIABETOLOGIA》 *
WILLIAM M. STEINBERG ET AL.: "LEADER 3—Lipase and Amylase Activity in Subjects WithType 2 Diabetes", 《PANCREAS》 *
吴晶 等: "CORE糖尿病模型预测利拉鲁肽联合二甲双胍治疗2型糖尿病的长期健康结果", 《中国新药与临床杂志》 *

Also Published As

Publication number Publication date
JP6940512B2 (ja) 2021-09-29
CA3013532A1 (en) 2017-09-08
ES2893755T3 (es) 2022-02-10
MX394179B (es) 2025-03-24
PH12018501844B1 (en) 2023-03-17
DK3423082T3 (da) 2021-10-11
AU2024201937A1 (en) 2024-04-11
EP3423082B1 (en) 2021-08-04
IL261169A (en) 2018-10-31
CN116327897A (zh) 2023-06-27
DK3423082T5 (da) 2023-02-06
CL2018002515A1 (es) 2018-11-09
WO2017149112A1 (en) 2017-09-08
US20180236038A1 (en) 2018-08-23
PH12018501844A1 (en) 2019-05-15
HRP20211492T1 (hr) 2021-12-24
MX2018010097A (es) 2018-11-09
US20170252408A1 (en) 2017-09-07
PL3423082T3 (pl) 2021-12-27
US9968659B2 (en) 2018-05-15
RU2018134061A3 (enExample) 2020-07-15
RU2018134061A (ru) 2020-04-06
KR102417455B1 (ko) 2022-07-06
MY195657A (en) 2023-02-03
IL261169B (en) 2019-11-28
JP2019507174A (ja) 2019-03-14
AU2017225841A1 (en) 2018-08-23
HUE055844T2 (hu) 2021-12-28
CA3013532C (en) 2019-07-23
EP3423082A1 (en) 2019-01-09
ZA201805538B (en) 2020-05-27
MA43704A (fr) 2021-04-14
BR112018067344A2 (pt) 2019-01-08
KR20180114168A (ko) 2018-10-17
SI3423082T1 (sl) 2021-10-29
RS62501B1 (sr) 2021-11-30
RU2745604C2 (ru) 2021-03-29

Similar Documents

Publication Publication Date Title
JP7221694B2 (ja) 心血管状態におけるセマグルチド
US12233114B2 (en) Method for treating diabetes
AU2024201937A1 (en) Liraglutide in cardiovascular conditions
US11673933B2 (en) Method for using insulin degludec for the improvement of glycemic control and reduction of acute and long-term diabetes complications
CN108883158A (zh) 用于肾脏病况的利拉鲁肽
CN108883159A (zh) 用于糖尿病性足溃疡的利拉鲁肽
HK1259166B (en) Liraglutide in cardiovascular conditions
HK1259166A1 (en) Liraglutide in cardiovascular conditions
BR122025010585A2 (pt) Uso de semaglutida para reduzir o risco de um evento cardiovascular adverso maior (mace) em indivíduos com diabetes mellitus tipo 2 e alto risco cardiovascular

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination